Efficacy and Safety of Low-dose Ticagrelor

• Status: Completed
• Trial end date: 2019-02-13
• Target enrollment: 0
• Participant gender: All

Summary

Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients. Recent study found that ticagrelor 90mg twice a day orally could significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular events. The previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in Chinese patients with stable CAD. But large-scale clinical trials are still needed to confirm the effects of low-dose ticagrelor on platelet function in Chinese patients with coronary heart disease.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital of Harbin Medical University
• Collaborators: Beijing Anzhen Hospital; RenJi Hospital; Shaanxi Provincial People's Hospital; Shengjing Hospital; The Central Hospital of Jia Mu Si City; The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Kunming Medical College; Tianjin Medical University General Hospital; Weifang People's Hospital; Wuhan Union Hospital, China
• Treatments: Clopidogrel; Ticagrelor

Criteria

Inclusion Criteria:

• Patients with coronary artery disease

Exclusion Criteria:

• younger than 18 years of age;

• anti-platelet therapy with clopidogrel or ticagrelor for less than 5 days;

• previous or current treatment with any other potentially confounding drugs.